Filter Results:
(479)
Show Results For
- All HBS Web (479)
- Faculty Publications (185)
Show Results For
- All HBS Web (479)
- Faculty Publications (185)
- Fast Answer
Biotech, Medical Devices, and Pharmaceuticals: Industry/Market Overview/Analysis
them for your industry research. BCC Research - Reports on major scientific and technological developments in biotech, medical devices, pharmaceutical, and high technology worldwide. EMIS – SWOT analysis, global and country... View Details
- 24 Apr 2014
- News
Giving hope and inspiration to cancer patients around the globe
Every new day is a good day for Kathryn E. Giusti (MBA 1985) since that morning in 1996 when her oncologist told her to get her affairs in order because she had a rare blood cancer, with three years to live. Leveraging her past experience as a View Details
George W. Merck
Merck played a pivotal role in the development of Merck & Company as a pharmaceutical research powerhouse. He created the firm’s first research division in 1933 and... View Details
Keywords: Healthcare
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Pharmaceutical Industry; Pharmaceutical Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
- February 2000 (Revised June 2003)
- Case
Pepcid AC: Racing to the OTC Market
By: Charles King III, Alvin J. Silk, Ernst R. Berndt and Lisa R. Klein
Pepcid management must decide whether to risk all in a race to be first in the over-the-counter market with a new heartburn remedy. View Details
Keywords: Competitive Advantage; Product Positioning; Markets; Research; Marketing Strategy; Product Development; Decision Choices and Conditions; Pharmaceutical Industry
King, Charles, III, Alvin J. Silk, Ernst R. Berndt, and Lisa R. Klein. "Pepcid AC: Racing to the OTC Market." Harvard Business School Case 500-073, February 2000. (Revised June 2003.)
- 08 Jun 2021
- News
New Funding for Female Founders
a patient’s home. “A pharmaceutical company, for instance, may want to study how well patients on a particular medication are able to sleep. HumanFirst can scan the clinical-research landscape to identify studies in which View Details
- April 2011
- Teaching Note
Office of Technology Transfer - Shanghai Institutes for Biological Sciences (TN)
By: Willy Shih and Sen Chai
Teaching Note for 611057. View Details
- 06 Feb 2007
- First Look
First Look: February 6, 2007
inventors, including knowledge spillovers and agglomeration and the concentration of spinoffs. This work investigates a possible antecedent of inventor mobility: regional variation in the enforcement of postemployment non-compete covenants. While previous View Details
Keywords: Martha Lagace
- Student-Profile
Byungyeon Kim
important Harvard’s worldwide research centers would be to his work. His second year research project involved a study of sales force compensation that resulted from a partnership with a Turkish View Details
- June 2014
- Supplement
Merrimack Pharmaceuticals, Inc. (B)
By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine
In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details
Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Edmondson, Amy C., Bethany Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 614-083, June 2014.
- 01 Mar 2007
- News
In Brief
Q&A with Daniel Vasella. Initially regarded by critics as too inexperienced to lead a major pharmaceutical company, Daniel Vasella (PMD 57, 1989) has set a new standard for innovation as CEO of Novartis. The Winning Season. Last year, St.... View Details
- Fast Answer
Investing in Life Sciences - SIP Resources
Market research: BCC Research - Reports on major economic, scientific, and technological developments in industrial, pharmaceutical, and high technology worldwide. Frost & Sullivan - Reports and market trends encompassing various... View Details
- 28 Feb 2019
- Cold Call Podcast
Pursuing Precision Medicine at Intermountain Healthcare
- 15 Dec 2024
- News
After Ozempic
Back before Ozempic, when Kate Mulroney (MBA 1984) spoke at technical conferences about her work at Novo Nordisk, people often assumed she was talking about Novartis. “I’d have to explain that’s a Swiss company; we’re Danish,” says Mulroney, now head of advanced... View Details
- 24 Oct 2016
- News
Health Care Pioneer Giusti Named McCance Senior Fellow at HBS
care, or engineering. Giusti currently serves as faculty cochair of the HBS-Kraft Precision Medicine Accelerator. She has more than two decades of experience in the pharmaceutical industry, having previously held senior positions at G. D.... View Details
Keywords: Susan Young
- 01 Jan 2003
- News
Daniel L. Vasella, M.D.
aspirations, purpose, and values, so that they work together as an aligned team." Dan Vasella finds that the skills he called upon as a practicing physician are equally useful in running one of the world's largest pharmaceutical... View Details
- May 2025
- Supplement
Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (D)
By: Linda A. Hill and Lydia Begag
This fourth installment in the Pfizer Global Clinical Supply (GCS) transformation case series highlights how over a decade of cultural and digital evolution positioned GCS to meet unprecedented global challenges. In 2011, Michael Ku became the Vice President of GCS and... View Details
Eugene N. Beesley
The first non-Lilly family member to serve as president, Beesley joined the pharmaceutical company at the age of 20, and worked in a variety of positions before becoming an executive level manger. Under Beesley’s leadership, View Details
Keywords: Healthcare
Richard M. Furlaud
Furlaud focused on Squibb's pharmaceuticals, investing in research and development that ultimately led to the introduction of several new drugs. Furlaud's streamlining and consistent support of the company's cardiovascular drugs paid off... View Details
Keywords: Healthcare
- 01 Jan 2002
- News
Raymond V. Gilmartin (MBA '68)
the business world has an important leadership role to play in terms of closing the gap in health and other vital social issues," he says. When Ray Gilmartin joined Merck in June 1994 as president and CEO (he became chairman several months later), it was the first time... View Details